Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vaxcyte Inc (NQ: PCVX ) 83.65 -1.51 (-1.77%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 579,580 Open 85.60 Bid (Size) 81.13 (1) Ask (Size) 86.49 (1) Prev. Close 85.16 Today's Range 83.37 - 87.71 52wk Range 44.20 - 87.71 Shares Outstanding 93,706,790 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Vaxcyte Appoints John Furey to Board of Directors July 02, 2024 From Vaxcyte, Inc. Via GlobeNewswire PCVX Stock Earnings: Vaxcyte Beats EPS for Q1 2024 May 08, 2024 PCVX stock results show that Vaxcyte beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Performance YTD +32.90% +32.90% 1 Month +12.28% +12.28% 3 Month +39.28% +39.28% 6 Month +31.94% +31.94% 1 Year +77.68% +77.68% More News Read More Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update May 08, 2024 From Vaxcyte, Inc. Via GlobeNewswire Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says April 10, 2024 Via Benzinga Recap: Vaxcyte Q4 Earnings February 27, 2024 Via Benzinga Earnings Scheduled For February 27, 2024 February 27, 2024 Via Benzinga Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference April 02, 2024 From Vaxcyte, Inc. Via GlobeNewswire Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday March 12, 2024 Via Benzinga Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants March 04, 2024 From Vaxcyte, Inc. Via GlobeNewswire Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update February 27, 2024 From Vaxcyte, Inc. Via GlobeNewswire Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 February 15, 2024 From Vaxcyte, Inc. Via GlobeNewswire Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares February 02, 2024 From Vaxcyte, Inc. Via GlobeNewswire Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference February 01, 2024 From Vaxcyte, Inc. Via GlobeNewswire Vaxcyte Announces Pricing of $750 Million Public Offering January 30, 2024 From Vaxcyte, Inc. Via GlobeNewswire Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants January 30, 2024 From Vaxcyte, Inc. Via GlobeNewswire Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older January 29, 2024 From Vaxcyte, Inc. Via GlobeNewswire Vaxcyte Appoints Whitney Jones as Chief People Officer January 16, 2024 From Vaxcyte, Inc. Via GlobeNewswire "Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales January 05, 2024 Via Benzinga Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise January 04, 2024 From Vaxcyte, Inc. Via GlobeNewswire Vaccine Player Vaxcyte Can Potentially Disrupt Pfizer's 20-Plus-Year Near Monopoly, Says Analyst December 07, 2023 Via Benzinga VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate December 04, 2023 From Vaxcyte, Inc. Via GlobeNewswire Vaxcyte Appoints Jacks Lee to Board of Directors November 28, 2023 From Vaxcyte, Inc. Via GlobeNewswire Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates November 27, 2023 From Vaxcyte, Inc. Via GlobeNewswire Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults November 09, 2023 From Vaxcyte, Inc. Via GlobeNewswire Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update November 06, 2023 From Vaxcyte, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
